

**UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK**

In re:

PURDUE PHARMA L.P., *et al.*,

Debtors.¹

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

**EIGHTH MONTHLY FEE STATEMENT OF FTI CONSULTING, INC. FOR
COMPENSATION FOR SERVICES RENDERED AND REIMBURSEMENT OF
EXPENSES INCURRED AS FINANCIAL ADVISOR TO THE AD HOC COMMITTEE
OF GOVERNMENTAL AND OTHER CONTINGENT LITIGATION CLAIMANTS FOR
THE PERIOD FROM MAY 1, 2020 THROUGH MAY, 31, 2020**

Name of Applicant:	FTI Consulting, Inc.
Authorized to provide Professional Services to:	Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants
Date of Order Approving Debtors' Payment of Fees and Expenses of Applicant:	December 2, 2019 [ECF No. 553]
Period for which compensation and reimbursement is sought:	May 1, 2020 through May 31, 2020
Monthly Fees Incurred:	\$303,367.00

¹ The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifesciences Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717), and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

Monthly Expenses Incurred: \$4,325.26

Total Fees and Expenses Due: \$307,692.26

This is a: X monthly _____ interim _____ final application

PRIOR APPLICATIONS:

Docket No./Filed	Compensation Period	Requested		Approved	
		Fees	Expenses	Fees	Expenses
Docket No. 635 Filed On 12/9/2019	9/19/2019 – 10/31/2019	\$778,791.50	\$680.61	\$623,033.20	\$680.61
Docket No. 741 Filed On 1/13/2020	11/1/2019 – 11/30/2019	\$827,575.00	\$899.41	\$662,060.00	\$899.41
Docket No. 852 Filed on 2/20/2020	12/1/2019 – 12/31/2019	\$802,036.50	\$2,284.19	\$641,629.20	\$2,284.19
Docket No. 916 Filed on 3/12/2020	1/1/2020 – 1/31/2020	\$774,662.00	\$11,530.84	\$619,729.60	\$11,530.84
Docket No. 1090 Filed on 4/27/2020	2/1/2020 – 2/29/2020	\$615,089.00	\$6,141.22	\$492,071.20	\$6,141.22
Docket No. 1171 Filed on 5/19/2020	3/1/2020 – 3/31/2020	\$561,863.50	\$67.08	\$449,490.80	\$67.08
Docket No. 1251 Filed on 6/10/2020	4/1/2020 – 4/30/2020	\$428,303.00	\$1,732.28	\$342,642.40	\$1,732.28

This statement (the “**Fee Statement**”) of FTI Consulting, Inc. (together with its wholly owned subsidiaries and independent contractors, “**FTI**”) as financial advisor to the Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants of Purdue Pharma L.P.,

et al. (the “**Committee**”) is submitted in accordance with the *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals* [ECF No. 529] and the *Order Authorizing the Debtors to Assume the Reimbursement Agreement and Pay the Fees and Expenses of the Ad Hoc Committee’s Professionals* [ECF No. 553] entered on November 21, 2019 and December 2, 2019, respectively, (the “**Orders**”). In support of this Fee Statement, FTI respectfully states as follows.

1. The fees and expenses for the period from May 1, 2020 through and including May 31, 2020 (the “**Eighth Fee Period**”) amount to:

Professional Fees	\$303,367.00
Expenses	4,325.26
TOTAL	<u>\$307,692.26</u>

2. In accordance with the Orders, FTI has separately recorded its fees in connection with or relating to the allocation of value among the Debtors’ creditors (the “**Allocation Fees**”) and has not, to the best of its knowledge, included Allocation Fees in this Fee Statement. If no timely and proper objection is made by a party-in-interest within fourteen (14) days after service of this Fee Statement, the Debtors are authorized to pay 80% of professional fees and 100% of out-of-pocket expenses. These amounts are presented below.

Professional Fees at 80%	\$242,693.60
Expenses at 100%	4,325.26
TOTAL	<u>\$247,018.86</u>

3. The professionals providing services, hourly billing rates, the aggregate hours worked by each professional, and the aggregate hourly fees for each professional during the Eighth Fee Period are set forth on the schedule annexed hereto as **Exhibit “A.”**

4. A summary of aggregate hours worked and aggregate hourly fees for each task code during the Eighth Fee Period is set forth on the schedule annexed hereto as **Exhibit “B.”**
5. Detailed time entry by task code during the Eighth Fee Period is set forth on the schedule annexed hereto as **Exhibit “C.”**
6. A summary of expenses incurred during the Eighth Fee Period is set forth on the schedule annexed hereto as **Exhibit “D.”**
7. Detailed breakdown of the expenses incurred during the Eighth Fee Period is set forth on the schedule annexed hereto as **Exhibit “E.”**
8. FTI reserves the right to request, in subsequent fee statements and applications, reimbursement of any additional expenses incurred during the Eighth Fee Period, as such expenses may not have been captured to date in FTI’s billing system.

NOTICE AND OBJECTION PROCEDURES

9. Objections to this Fee Statement, if any, must be filed with the Court and served upon the Notice Parties so as to be received no later than July 27, 2020 (the “Objection Deadline”), setting forth the nature of the objection and the amount of fees or expenses at issue (an “Objection”).
10. If no objections to this Fee Statement are filed and served as set forth above, the Debtors shall promptly pay eighty percent (80%) of the fees and one hundred percent (100%) of the expenses identified herein.
11. If an objection to this Fee Statement is received on or before the Objection Deadline, the Debtors shall withhold payment of that portion of this Fee Statement to which the objection is directed and promptly pay the remainder of the fees and disbursements in the percentages set forth above. To the extent such an objection is not resolved, it shall be

preserved and scheduled for consideration at the next interim fee application hearing to be heard by the Court.

Dated: New York, New York
July 13, 2020

FTI CONSULTING, INC.
Financial Advisors to the Ad Hoc Committee of
Governmental and Other Contingent Litigation
Claimants of Purdue Pharma L.P.

By: /s/ Matthew Diaz
Matthew Diaz, Senior Managing Director
Three Times Square, 10th Floor
New York, New York 10036
Telephone: (212) 499-3611
Email: matt.diaz@fticonsulting.com

EXHIBIT A

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
SUMMARY OF HOURS BY PROFESSIONAL
FOR THE PERIOD MAY 1, 2020 TO MAY 31, 2020

Professional	Position	Specialty	Billing Rate¹	Total Hours	Total Fees
Diaz, Matthew	Sr Managing Director	Restructuring	\$ 1,085	49.7	\$ 53,924.50
Greenblatt, Matthew	Sr Managing Director	Forensics	985	4.2	4,137.00
Joffe, Steven	Sr Managing Director	Tax	1,125	18.0	20,250.00
Simms, Steven	Sr Managing Director	Restructuring	1,295	2.8	3,626.00
Kyviakidis, Peter	Managing Director	Forensics	765	7.4	5,661.00
Costaldo, Nicole	Sr Director	Forensics	700	5.8	4,060.00
Suric, Emil	Sr Director	Healthcare	820	4.0	3,280.00
Bromberg, Brian	Director	Restructuring	815	170.6	139,039.00
Kim, Ye Darm	Sr Consultant	Restructuring	560	75.4	42,224.00
Tirabassi, Kathryn	Sr Consultant	Restructuring	560	8.1	4,536.00
Mazzari, Meredith	Sr Consultant	Forensics	530	10.4	5,512.00
Kurtz, Emma	Consultant	Restructuring	415	40.1	16,641.50
Hellmund-Mora, Marili	Associate	Restructuring	280	1.7	476.00
GRAND TOTAL				398.2	\$ 303,367.00

1. Billing rates of international professionals have been translated to USD using the relevant spot rate.

EXHIBIT B**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649****SUMMARY OF HOURS BY TASK****FOR THE PERIOD MAY 1, 2020 TO MAY 31, 2020**

Task Code	Task Description	Total Hours	Total Fees
1	Current Operating Results & Events	17.0	\$ 10,419.50
2	Cash & Liquidity Analysis	6.9	4,676.00
7	Analysis of Domestic Business Plan	149.4	114,753.50
10	Analysis of Tax Issues	33.1	32,922.50
13	Analysis of Other Miscellaneous Motions	1.2	672.00
16	Analysis, Negotiate and Form of POR & DS	5.2	4,103.00
18	Review of Historical Transactions	32.3	22,866.00
19	Case Management	6.8	5,358.50
21	General Mtgs with Counsel and/or Ad Hoc Committee	5.6	5,656.00
22	Meetings with Other Parties	6.4	5,894.00
24	Preparation of Fee Application	10.7	5,988.50
28	Review of IAC Business Plan	123.6	90,057.50
GRAND TOTAL¹		398.2	\$ 303,367.00

1. Billing rates of international professionals have been translated to USD using the relevant spot rate.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD MAY 1, 2020 TO MAY 31, 2020

Task Category	Date	Professional	Hours	Activity
1	5/1/2020	Diaz, Matthew	0.6	Develop outline re: HRT funding presentation.
1	5/1/2020	Kurtz, Emma	0.5	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	5/4/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	5/5/2020	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	5/6/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	5/7/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	5/8/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	5/11/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	5/12/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	5/13/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	5/14/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	5/15/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	5/18/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	5/19/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	5/20/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	5/21/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	5/22/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	5/25/2020	Diaz, Matthew	0.5	Review operating results re: the monitor report.
1	5/26/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	5/26/2020	Bromberg, Brian	1.3	Review Debtors' March YTD operating report.
1	5/27/2020	Kim, Ye Darm	0.4	Participate in call re: March operating results.
1	5/27/2020	Kim, Ye Darm	1.8	Prepare draft presentation re: March operating report.
1	5/27/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	5/27/2020	Bromberg, Brian	2.0	Prepare revisions to March YTD operating report slides.
1	5/28/2020	Kim, Ye Darm	0.4	Update budget to actual analysis of March operating results.
1	5/28/2020	Kim, Ye Darm	0.9	Prepare budget to actual analysis of March operating results.
1	5/28/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	5/28/2020	Bromberg, Brian	2.0	Continue preparing revisions to March YTD operating report slides.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD MAY 1, 2020 TO MAY 31, 2020

Task Category	Date	Professional	Hours	Activity
1	5/29/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1 Total			17.0	
2	5/6/2020	Kim, Ye Darm	1.1	Analyze variances between latest cash update and the revised business plan.
2	5/26/2020	Costaldo, Nicole	2.1	Conduct preliminary review of supporting documents provided re: Cash Transfers of Value report
2	5/27/2020	Costaldo, Nicole	1.5	Attend meeting with the forensic accounting team re: plan of action for detailed inventory of documents and information relied upon for the Cash Transfers of Value report
2	5/29/2020	Costaldo, Nicole	2.2	Build out questions and information requests for AlixPartners re: Cash Transfers analysis
2 Total			6.9	
7	5/1/2020	Diaz, Matthew	1.2	Review HRT responses to our due diligence questions.
7	5/1/2020	Kim, Ye Darm	0.4	Participate in call re: revised US business plan diligence.
7	5/1/2020	Kim, Ye Darm	1.3	Prepare draft of revised US business plan diligence presentation.
7	5/1/2020	Bromberg, Brian	1.8	Review the revised US business plan provided by the Debtors.
7	5/2/2020	Diaz, Matthew	0.6	Participate in a call with the Debtors to discuss the HRT motion.
7	5/2/2020	Diaz, Matthew	0.7	Preparation for the call on the HRT motion.
7	5/2/2020	Kim, Ye Darm	2.3	Continue preparation of draft revised US business plan diligence presentation.
7	5/3/2020	Diaz, Matthew	0.6	Review due diligence responses to HRT diligence questions.
7	5/4/2020	Diaz, Matthew	1.6	Review a draft of HRT diligence presentation to the Committee.
7	5/4/2020	Kim, Ye Darm	2.1	Process updates to revised US business plan diligence presentation.
7	5/4/2020	Kim, Ye Darm	1.4	Continue processing revisions to the revised US business plan presentation.
7	5/5/2020	Diaz, Matthew	0.5	Review the updated report to the committee on HRT funding.
7	5/5/2020	Kim, Ye Darm	2.3	Process revisions to revised US business plan diligence presentation.
7	5/5/2020	Kim, Ye Darm	0.6	Participate in internal discussion re: revised US business plan diligence.
7	5/5/2020	Kim, Ye Darm	1.9	Update revised US business plan diligence presentation.
7	5/5/2020	Kim, Ye Darm	1.8	Review Debtors' revised business plan support files for financial information.
7	5/5/2020	Bromberg, Brian	1.1	Review February domestic business plan to compare variances and changes in assumptions.
7	5/5/2020	Bromberg, Brian	1.1	Review revised domestic business plan to compare variances and changes in assumptions from prior version.
7	5/5/2020	Bromberg, Brian	2.7	Review US business plan backup files provided in dataroom.
7	5/5/2020	Bromberg, Brian	1.8	Continue to review business plan diligence files in the dataroom.
7	5/6/2020	Diaz, Matthew	0.9	Review an updated draft of the HRT funding presentation to the Committee.
7	5/6/2020	Kim, Ye Darm	2.7	Prepare updates to revised US business plan presentation.
7	5/6/2020	Bromberg, Brian	3.4	Review latest revised business plan presentation prepare revisions.
7	5/6/2020	Bromberg, Brian	0.4	Discuss US business plan with Houlihan.
7	5/6/2020	Bromberg, Brian	3.5	Review April updated business plan and variance presentation.
7	5/7/2020	Diaz, Matthew	2.1	Review the Debtors revised April business plan.
7	5/7/2020	Kim, Ye Darm	3.1	Process revisions to revised US business plan diligence presentation.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD MAY 1, 2020 TO MAY 31, 2020

Task Category	Date	Professional	Hours	Activity
7	5/7/2020	Kim, Ye Darm	1.6	Continue processing revisions to revised US business plan diligence presentation.
7	5/7/2020	Bromberg, Brian	1.1	Finalize version of business plan presentation to send to team.
7	5/7/2020	Bromberg, Brian	1.3	Review business plan and incorporate revisions to latest version of diligence presentation.
7	5/7/2020	Bromberg, Brian	2.7	Compare Rhodes product forecasts to prior business plan.
7	5/7/2020	Bromberg, Brian	2.6	Continue review of Rhodes product level forecasts and incorporate changes to commentary.
7	5/8/2020	Diaz, Matthew	2.6	Perform detailed review of the business plan presentation to the subcommittee.
7	5/8/2020	Diaz, Matthew	1.5	Review the Debtors' revised business plan.
7	5/8/2020	Kim, Ye Darm	1.2	Process revisions to revised US business plan diligence questions list.
7	5/8/2020	Kim, Ye Darm	2.1	Process revisions to revised US business plan diligence presentation.
7	5/8/2020	Bromberg, Brian	1.8	Review and clarify diligence request questions for Debtors.
7	5/9/2020	Bromberg, Brian	1.4	Review business plan and edit latest version of US business plan diligence presentation.
7	5/11/2020	Diaz, Matthew	1.3	Review latest version of the domestic business plan analysis.
7	5/11/2020	Kim, Ye Darm	1.3	Process updates to domestic business plan diligence presentation.
7	5/11/2020	Kim, Ye Darm	0.8	Process revisions to US business plan diligence questions list.
7	5/11/2020	Kim, Ye Darm	0.7	Update list of revised domestic business plan diligence questions.
7	5/11/2020	Kim, Ye Darm	1.7	Process revisions to the domestic business plan diligence update deck.
7	5/11/2020	Kim, Ye Darm	1.0	Participate in internal meeting re: revised US business plan diligence presentation.
7	5/11/2020	Bromberg, Brian	2.3	Process revisions to presentation re: new US business plan.
7	5/11/2020	Bromberg, Brian	1.2	Review US business plan backup files provided in dataroom.
7	5/11/2020	Bromberg, Brian	1.0	Prepare for internal business plan discussion with team.
7	5/11/2020	Bromberg, Brian	1.0	Participate in internal meeting re: US business plan.
7	5/12/2020	Diaz, Matthew	0.3	Review the updated HRT proposal.
7	5/12/2020	Diaz, Matthew	0.5	Participate in call with the UCC professionals to discuss the HRT motion.
7	5/13/2020	Kim, Ye Darm	0.4	Process revisions to US business plan segment update deck to redact privileged information.
7	5/13/2020	Bromberg, Brian	0.7	Review follow up requests list for the NCSG.
7	5/13/2020	Bromberg, Brian	0.8	Review the updated US business plan request list.
7	5/13/2020	Bromberg, Brian	1.1	Review protective order stipulations for business plan summary.
7	5/14/2020	Bromberg, Brian	0.6	Coordinate responses to NCSG follow up questions with other advisors.
7	5/18/2020	Diaz, Matthew	0.9	Review the updated revised US business plan analysis.
7	5/18/2020	Kim, Ye Darm	1.2	Prepare summaries of documents and information referenced re: US business plan presentation.
7	5/18/2020	Kim, Ye Darm	0.9	Review PJT domestic business sale considerations presentation.
7	5/18/2020	Kim, Ye Darm	1.6	Review latest productions from Debtors for revised business plan support files.
7	5/18/2020	Kim, Ye Darm	1.9	Review non-PEO version of revised business plan and update presentation for confidential information.
7	5/18/2020	Bromberg, Brian	0.8	Review January 2020 US business plan deck versus protective order.
7	5/18/2020	Bromberg, Brian	1.1	Review Project Windsor discussion materials in the dataroom.
7	5/18/2020	Bromberg, Brian	3.3	Review and edit latest US business plan presentation.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD MAY 1, 2020 TO MAY 31, 2020

Task Category	Date	Professional	Hours	Activity
7	5/19/2020	Kim, Ye Darm	0.3	Participate in follow up call re: Purdue workstreams
7	5/19/2020	Kim, Ye Darm	0.5	Update US business plan diligence presentation.
7	5/21/2020	Bromberg, Brian	1.3	Review dataroom for domestic business plan backup.
7	5/21/2020	Bromberg, Brian	0.7	Review status of domestic diligence questions.
7	5/22/2020	Diaz, Matthew	0.9	Review the updated PJT valuation analysis.
7	5/26/2020	Kim, Ye Darm	0.8	Review Debtors' latest production and review business plan financial support.
7	5/26/2020	Bromberg, Brian	1.1	Review IQVIA product level data re: Rhodes generic products.
7	5/26/2020	Bromberg, Brian	2.8	Review new domestic business plan support files uploaded to dataroom.
7	5/27/2020	Diaz, Matthew	0.9	Review the Debtors' responses to the domestic open item questions.
7	5/27/2020	Kim, Ye Darm	0.3	Update revised US business plan diligence presentation.
7	5/27/2020	Kim, Ye Darm	0.4	Review and update summary of documents referenced re: business plan diligence presentation.
7	5/27/2020	Bromberg, Brian	2.3	Finalize and send draft of domestic business plan presentation to Houlihan Lokey.
7	5/27/2020	Bromberg, Brian	0.4	Respond to outstanding questions re: domestic business plan diligence.
7	5/27/2020	Bromberg, Brian	2.1	Process revisions to the domestic business plan presentation.
7	5/27/2020	Bromberg, Brian	0.6	Participate in discussion re: revised domestic business plan with team.
7	5/28/2020	Diaz, Matthew	0.6	Review the updated Purdue domestic presentation to the AHC.
7	5/28/2020	Kim, Ye Darm	0.3	Prepare revisions to the updated US business plan diligence deck.
7	5/28/2020	Bromberg, Brian	1.8	Process revisions to the domestic business plan presentation.
7	5/29/2020	Bromberg, Brian	1.3	Review latest draft of domestic business plan presentation.
7	5/29/2020	Bromberg, Brian	0.7	Prepare and request additional diligence requests re: Rhodes forecasts.
7	5/29/2020	Bromberg, Brian	0.8	Review information re: Rhodes product data.
7	5/4/2020	Suric, Emil	0.5	Review outstanding diligence items to prepare Rhodes due diligence and data request.
7	5/6/2020	Suric, Emil	1.0	Participate in call re: due diligence status for Rhodes data.
7	5/8/2020	Suric, Emil	0.5	Review latest Rhodes product level information to diligence reasonableness of forecasts.
7	5/29/2020	Suric, Emil	1.5	Review Rhodes product data provided by Debtors for forecast diligence.
7	5/29/2020	Suric, Emil	0.5	Participate in internal meeting re: next steps for diligence of forecasts and other open items.
7	5/1/2020	Bromberg, Brian	0.9	Prepare for call on HRT funding motion.
7	5/1/2020	Bromberg, Brian	3.1	Review HRT funding motion and provided diligence documents.
7	5/2/2020	Kim, Ye Darm	1.9	Prepare presentation re: HRT diligence update.
7	5/2/2020	Kim, Ye Darm	1.1	Participate in call w/ Debtors re: HRT motion diligence.
7	5/2/2020	Kim, Ye Darm	0.4	Participate in internal call re: HRT motion diligence workplan.
7	5/2/2020	Bromberg, Brian	0.5	Participate in internal call on HRT funding motion.
7	5/2/2020	Bromberg, Brian	2.1	Prepare additional slides for presentation on HRT budget.
7	5/2/2020	Bromberg, Brian	2.0	Review materials and prepare for call on HRT funding motion.
7	5/3/2020	Kim, Ye Darm	1.1	Process revisions to HRT diligence update presentation.
7	5/3/2020	Bromberg, Brian	1.3	Review updated HRT diligence presentation and prepare revisions.
7	5/4/2020	Kim, Ye Darm	0.5	Participate in meeting re: HRT diligence update presentation.
7	5/4/2020	Kim, Ye Darm	0.9	Process revisions to HRT update diligence deck.
7	5/4/2020	Kim, Ye Darm	0.4	Continue processing revisions to HRT update diligence deck.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD MAY 1, 2020 TO MAY 31, 2020

Task Category	Date	Professional	Hours	Activity
7	5/4/2020	Kim, Ye Darm	1.1	Process revisions to HRT diligence update presentation.
7	5/4/2020	Bromberg, Brian	2.1	Prepare comments for revision on HRT diligence presentation.
7	5/4/2020	Bromberg, Brian	2.4	Review latest draft of HRT presentation.
7	5/4/2020	Bromberg, Brian	2.6	Process revisions to HRT diligence update presentation.
7	5/5/2020	Bromberg, Brian	0.5	Prepare additional diligence requests re: HRT.
7	5/5/2020	Bromberg, Brian	1.5	Incorporate comments from Counsel on HRT presentation.
7	5/6/2020	Bromberg, Brian	0.7	Review confidentiality designations on HRT documents.
7	5/6/2020	Bromberg, Brian	2.3	Participate in AHC call re: HRT funding.
7	5/6/2020	Bromberg, Brian	0.5	Review and update HRT presentation.
7	5/6/2020	Bromberg, Brian	1.4	Incorporate comments from Counsel on HRT presentation.
7	5/6/2020	Bromberg, Brian	0.6	Prepare additional diligence requests re: HRT.
7	5/11/2020	Bromberg, Brian	0.4	Review HRT motion diligence responses.
7 Total			149.4	
10	5/1/2020	Joffe, Steven	0.6	Review memo to committee professionals re: Tax Considerations.
10	5/5/2020	Joffe, Steven	0.7	Review memos from BR for tax-related matters.
10	5/6/2020	Diaz, Matthew	0.5	Review latest analysis and considerations re: IAC tax issues.
10	5/8/2020	Joffe, Steven	0.9	Conduct research on unrelated business income tax structures re: IACs.
10	5/12/2020	Joffe, Steven	1.0	Review trust documents for potential tax considerations.
10	5/12/2020	Joffe, Steven	0.3	Review precedent tax rulings for potential tax considerations.
10	5/12/2020	Joffe, Steven	1.3	Participate in weekly AHC call re: potential tax issues.
10	5/13/2020	Joffe, Steven	3.3	Review latest KPMG tax materials.
10	5/13/2020	Joffe, Steven	1.3	Participate in call with KPMG re: tax considerations.
10	5/13/2020	Diaz, Matthew	0.9	Review of the KPMG tax materials in preparation for the call with KPMG tax.
10	5/13/2020	Diaz, Matthew	1.4	Participate on tax call with KPMG re IAC tax.
10	5/13/2020	Bromberg, Brian	1.0	Participate in tax call with KPMG on IACs.
10	5/14/2020	Joffe, Steven	1.0	Participate in weekly call with Counsel re: tax issues.
10	5/14/2020	Joffe, Steven	0.4	Review Brown Rudnick tax considerations deck.
10	5/14/2020	Joffe, Steven	0.8	Review potential tax refund calculations.
10	5/14/2020	Bromberg, Brian	0.9	Review analysis re: tax refund impact on Purdue.
10	5/14/2020	Bromberg, Brian	0.5	Participate in internal tax diligence call re: recent updates.
10	5/15/2020	Joffe, Steven	1.0	Revisions to analysis re: estimated tax refunds
10	5/15/2020	Kim, Ye Darm	0.6	Process revisions to slide re: tax refund analysis.
10	5/15/2020	Kim, Ye Darm	0.6	Update analysis re: potential tax refunds.
10	5/15/2020	Kim, Ye Darm	0.6	Participate in internal discussion re: tax refund analysis.
10	5/15/2020	Bromberg, Brian	1.0	Participate in internal discussion re: tax refund analysis.
10	5/15/2020	Bromberg, Brian	0.7	Review potential tax refund impact on Purdue.
10	5/18/2020	Joffe, Steven	0.6	Participate in internal discussion re: tax refund analysis.
10	5/18/2020	Diaz, Matthew	0.6	Review analysis on tax refund impact to Purdue.
10	5/18/2020	Kim, Ye Darm	0.7	Process revisions to presentation re: tax refund analysis.
10	5/18/2020	Kim, Ye Darm	0.3	Participate in internal meeting re: tax refund analysis.
10	5/18/2020	Bromberg, Brian	0.5	Process revisions to analysis re: tax refunds.
10	5/19/2020	Joffe, Steven	0.7	Review updated presentation re: tax refund analysis.
10	5/20/2020	Joffe, Steven	1.2	Participate in Committee Call re: tax considerations.
10	5/21/2020	Joffe, Steven	1.0	Participate in weekly call with Counsel re: tax issues.
10	5/21/2020	Joffe, Steven	0.9	Correspond with Counsel re: tax considerations.
10	5/21/2020	Joffe, Steven	0.7	Continue correspondence with Counsel re: tax considerations.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD MAY 1, 2020 TO MAY 31, 2020

Task Category	Date	Professional	Hours	Activity
10	5/21/2020	Bromberg, Brian	1.2	Review tax responses to Counsel and provide feedback.
10	5/21/2020	Bromberg, Brian	0.5	Participate in AHC tax update call.
10	5/21/2020	Bromberg, Brian	1.0	Review KPMG materials on tax considerations.
10	5/22/2020	Diaz, Matthew	0.6	Review the IAC tax analysis.
10	5/28/2020	Joffe, Steven	0.3	Participate in call with Counsel re: tax considerations.
10	5/28/2020	Bromberg, Brian	0.5	Prepare summary of update for tax group.
10	5/28/2020	Bromberg, Brian	0.5	Participate in call with Counsel re: tax considerations.
10 Total			33.1	
13	5/13/2020	Kim, Ye Darm	1.2	Review latest production from DPW re: historical complaints.
13 Total			1.2	
16	5/19/2020	Diaz, Matthew	1.2	Review the updated draft RSA.
16	5/19/2020	Kim, Ye Darm	1.2	Review draft RSA for financial issues to track
16	5/19/2020	Kim, Ye Darm	0.6	Review Counsel's memo re: RSA issues.
16	5/19/2020	Bromberg, Brian	2.2	Review the updated draft RSA and identify key issues.
16 Total			5.2	
18	5/26/2020	Greenblatt, Matthew	1.7	Review document production and data made available in the Data Room by Alix Partners and Davis Polk related to Alix Partners Cash Transfers Report
18	5/26/2020	Greenblatt, Matthew	0.8	Participate in discussions with FTI team and correspondence with Committee counsel to prepare for document production by Alix Partners.
18	5/27/2020	Greenblatt, Matthew	0.5	Develop workplan for review of Alix Partners work product
18	5/29/2020	Greenblatt, Matthew	1.2	Continue review of document production and data provided by Alix Partners and Davis Polk related to Alix Partners Cash Transfers Report
18	5/1/2020	Diaz, Matthew	0.4	Draft correspondence to counsel re: cash transfer analysis.
18	5/22/2020	Bromberg, Brian	0.5	Review dataroom for newly uploaded files re: cash transfer report.
18	5/26/2020	Diaz, Matthew	0.6	Review latest update to cash transfer analysis.
18	5/26/2020	Kyviakidis, Peter	0.8	Participate in internal team meeting re: Cash Transfers of Value Analysis prepared by AlixPartners.
18	5/26/2020	Kyviakidis, Peter	0.5	Participate in meeting to discuss scope investigatory work re: Cash Transfers Of Value Analysis prepared by AlixPartners.
18	5/26/2020	Bromberg, Brian	0.5	Participate in discussion re: cash transfer report.
18	5/26/2020	Bromberg, Brian	0.7	Compile list of known parties for cash transfer report.
18	5/27/2020	Mazzari, Meredith	1.1	Participate in internal meeting to determine scope of workplan re: cash transfers of value
18	5/27/2020	Kyviakidis, Peter	1.0	Participate in discussion on scope of work re: Cash Transfers of Value Analysis prepared by AlixPartners.
18	5/27/2020	Kyviakidis, Peter	0.8	Participate in meeting re: GRIP Group's investigatory work in relation to the Cash Transfers of Value Analysis prepared by AlixPartners.
18	5/27/2020	Kyviakidis, Peter	2.8	Draft a detailed information request re: Cash Transfers of Value Analysis prepared by AlixPartners.
18	5/27/2020	Bromberg, Brian	0.8	Review and prepare updated list of known parties re: cash transfers report.
18	5/28/2020	Mazzari, Meredith	2.5	Review and document files provided by AlixPartners in connection with Cash Transfers of Value Analysis.
18	5/29/2020	Diaz, Matthew	0.9	Perform initial review of the non cash transfer report.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD MAY 1, 2020 TO MAY 31, 2020

Task Category	Date	Professional	Hours	Activity
18	5/29/2020	Mazzari, Meredith	1.3	Review diligence documents received to identify outstanding items within Appendix A of Cash Transfers of Value Analysis.
18	5/29/2020	Mazzari, Meredith	1.5	Participate in internal meeting re: outstanding inquiries on the cash transfers report.
18	5/29/2020	Mazzari, Meredith	2.3	Review and documentation of files provided by AlixPartners in connection with Cash Transfers of Value Analysis
18	5/29/2020	Kim, Ye Darm	0.8	Prepare summary of report 1B for internal use.
18	5/29/2020	Kim, Ye Darm	2.9	Review report 1B re: non-cash transfers.
18	5/29/2020	Kim, Ye Darm	1.6	Continue review of report 1B re: non-cash transfers.
18	5/29/2020	Kyviakidis, Peter	1.5	Participate in meeting to discuss diligence and information requests re: Cash Transfers of Value Analysis prepared by AlixPartners.
18	5/29/2020	Bromberg, Brian	0.6	Review non-cash transfers report.
18	5/31/2020	Mazzari, Meredith	0.5	Confirm whether documents contained within Appendix A of Cash Transfers of Value Analysis have been received by FTI
18	5/31/2020	Mazzari, Meredith	0.5	Participate in correspondence re: review and documentation of files provided by AlixPartners in connection with Cash Transfers of Value Analysis
18	5/31/2020	Mazzari, Meredith	0.7	Review Cash Transfers of Value Analysis for scope of each of the cash distribution categories
18 Total			32.3	
19	5/5/2020	Kurtz, Emma	0.4	Prepare updates to dataroom index to incorporate recently shared documents to share with team.
19	5/8/2020	Simms, Steven	0.4	Participate in correspondence re: case status and ongoing diligence.
19	5/11/2020	Kurtz, Emma	0.9	Update dataroom index to include recently added documents to share with team.
19	5/12/2020	Simms, Steven	0.6	Participate in correspondence re: case status and ongoing diligence.
19	5/14/2020	Simms, Steven	0.4	Participate in correspondence re: case status and ongoing diligence.
19	5/18/2020	Kurtz, Emma	1.3	Update dataroom index to include recently uploaded files to share update with team.
19	5/19/2020	Simms, Steven	0.6	Participate in correspondence re: case status and ongoing diligence.
19	5/22/2020	Simms, Steven	0.4	Participate in correspondence re: case status and ongoing diligence.
19	5/26/2020	Kurtz, Emma	0.9	Update dataroom index to include recently uploaded information to share with team.
19	5/27/2020	Simms, Steven	0.4	Participate in correspondence re: case status and ongoing diligence.
19	5/27/2020	Kim, Ye Darm	0.5	Participate in call re: Purdue workstreams.
19 Total			6.8	
21	5/6/2020	Diaz, Matthew	2.2	Participate in the weekly ad hoc committee call.
21	5/12/2020	Diaz, Matthew	1.6	Participate on a call with the ad hoc committee to discuss the hart funding motion, abatement issues and monitor update.
21	5/21/2020	Kim, Ye Darm	0.8	Participate in AHC follow up call re: term sheet considerations.
21	5/27/2020	Diaz, Matthew	1.0	Participate on the AHC call re: ongoing due diligence.
21 Total			5.6	
22	5/1/2020	Diaz, Matthew	1.1	Participate in a call with the DOJ to discuss their questions on the domestic and international operations.
22	5/14/2020	Diaz, Matthew	0.8	Review diligence responses to the non-consenting states group.
22	5/15/2020	Diaz, Matthew	0.3	Review follow up items from call with the non consenting states and send related correspondence to the group.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD MAY 1, 2020 TO MAY 31, 2020

Task Category	Date	Professional	Hours	Activity
22	5/15/2020	Diaz, Matthew	0.9	Participate in call with HL and KL to prepare for the meeting with the non consenting states.
22	5/15/2020	Diaz, Matthew	1.3	Participate on a call with the non consenting states re: financial and diligence update.
22	5/15/2020	Kim, Ye Darm	0.8	Participate in pre-call with counsel prior to NCSG call.
22	5/15/2020	Kim, Ye Darm	1.2	Participate in NCSG call re: diligence.
22 Total			6.4	
24	5/4/2020	Hellmund-Mora, Marili	0.5	Generate fee and cost estimate in connection with reporting budget and fee application.
24	5/18/2020	Hellmund-Mora, Marili	0.5	Generate fee and cost estimate in connection with reporting budget and fee application.
24	5/19/2020	Tirabassi, Kathryn	1.4	Finalize March 2020 Fee Statement.
24	5/19/2020	Tirabassi, Kathryn	0.6	Begin to prepare April 2020 Fee Statement.
24	5/20/2020	Hellmund-Mora, Marili	0.7	Finalize the March fee application.
24	5/20/2020	Tirabassi, Kathryn	0.4	Prepare April 2020 Fee Statement.
24	5/21/2020	Tirabassi, Kathryn	0.5	Prepare April 2020 Fee Statement.
24	5/22/2020	Tirabassi, Kathryn	2.1	Prepare April 2020 Fee Statement.
24	5/25/2020	Tirabassi, Kathryn	2.2	Prepare April 2020 Fee Statement.
24	5/26/2020	Diaz, Matthew	0.9	Review of the April bill.
24	5/26/2020	Tirabassi, Kathryn	0.3	Finalize April 2020 Fee Statement.
24	5/27/2020	Tirabassi, Kathryn	0.6	Finalize April 2020 Fee Statement.
24 Total			10.7	
28	5/1/2020	Kurtz, Emma	1.4	Review question list on changes in IAC sales projections to update list to include additional information received in the revised IAC budget.
28	5/1/2020	Kurtz, Emma	1.6	Analyze variances between the revised budget received in March and the revised IAC budget received on April 29.
28	5/1/2020	Kurtz, Emma	2.1	Continue to analyze country-level variances between the original budget and the revised budget to the business plan.
28	5/1/2020	Bromberg, Brian	0.9	Review previously provided price and volume information re: IAC business plan.
28	5/1/2020	Bromberg, Brian	0.8	Review product variance issues on IACs.
28	5/3/2020	Bromberg, Brian	1.3	Review diligence responses to Europe diligence questions re: IACs.
28	5/4/2020	Kurtz, Emma	1.2	Analyze variance between 2019 actuals in the revised P&L and the previous figures received from Steve Jamieson.
28	5/4/2020	Kurtz, Emma	0.8	Prepare revised diligence questions for the Company on changes in sales projections by country by product.
28	5/4/2020	Kurtz, Emma	1.7	Analyze sales variances between the revised P&L and the previously received price/volume data.
28	5/4/2020	Bromberg, Brian	1.1	Review IAC business plan variances by product.
28	5/4/2020	Bromberg, Brian	1.4	Compare 2019 actuals provided for IACs to prior business plan forecasts.
28	5/4/2020	Bromberg, Brian	1.0	Compile status and follow up review on IAC outstanding diligence.
28	5/5/2020	Kurtz, Emma	1.1	Prepare summary analysis of revised IAC budget P&L line items by entity.
28	5/5/2020	Kurtz, Emma	1.2	Prepare summary analysis of revised IAC budget to evaluate changes.
28	5/5/2020	Bromberg, Brian	0.9	Review entity summary of new IAC P&L.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD MAY 1, 2020 TO MAY 31, 2020

Task Category	Date	Professional	Hours	Activity
28	5/6/2020	Bromberg, Brian	1.1	Review and compile historical presentations for information sharing protocol.
28	5/11/2020	Diaz, Matthew	1.4	Review the updated IAC business plan analysis.
28	5/11/2020	Kim, Ye Darm	0.8	Prepare diligence materials and presentations for NCSG.
28	5/11/2020	Kim, Ye Darm	0.3	Participate in internal discussion re: IAC workstreams and next steps.
28	5/11/2020	Kim, Ye Darm	0.5	Participate in internal discussion re: IAC diligence workplan.
28	5/11/2020	Kurtz, Emma	0.6	Discuss progress of IAC 2020 business plan review and next steps.
28	5/11/2020	Bromberg, Brian	1.8	Create priority diligence request list re: IACs.
28	5/11/2020	Bromberg, Brian	0.5	Participate in discussion with IAC diligence with internal team.
28	5/11/2020	Bromberg, Brian	1.3	Update latest priority diligence request list re: IACs.
28	5/12/2020	Diaz, Matthew	0.8	Participate in a call with the Debtors re: IAC due diligence.
28	5/12/2020	Diaz, Matthew	0.9	Prepare for the call with the Debtors re: the IAC due diligence.
28	5/12/2020	Diaz, Matthew	0.6	Develop outline of updates re: IAC diligence presentation.
28	5/12/2020	Kim, Ye Darm	0.2	Consolidate prior presentations to share with the NCSG.
28	5/12/2020	Kim, Ye Darm	0.4	Participate in meeting re: IAC diligence next steps.
28	5/12/2020	Kim, Ye Darm	1.4	Continue preparing analysis re: YEE v. Actual 2019 results.
28	5/12/2020	Kim, Ye Darm	0.6	Participate in internal meeting re: IAC diligence workplan.
28	5/12/2020	Kim, Ye Darm	2.1	Prepare analysis re: YEE v. Actuals for 2019.
28	5/12/2020	Kurtz, Emma	0.3	Discuss outstanding IAC diligence requests and preparation of presentation for Counsel to explain diligence process.
28	5/12/2020	Kurtz, Emma	1.6	Prepare variance analysis between revised budget and original budget re: preparation of deck for Counsel on diligence process.
28	5/12/2020	Bromberg, Brian	1.1	Discuss IAC diligence requests with Debtor advisors.
28	5/12/2020	Bromberg, Brian	0.7	Participate in internal diligence meeting with team re: IAC.
28	5/12/2020	Bromberg, Brian	2.3	Review new diligence requests posted to dataroom re: IACs.
28	5/12/2020	Bromberg, Brian	1.1	Review prior diligence requests to materials received re: IACs.
28	5/12/2020	Bromberg, Brian	1.1	Prepare information sharing presentations for NCSG.
28	5/12/2020	Bromberg, Brian	0.8	Continue review of prior diligence requests to materials received re: IACs.
28	5/12/2020	Bromberg, Brian	2.3	Finalize priority IAC diligence request list to send to Debtor advisors.
28	5/13/2020	Kim, Ye Darm	0.3	Prepare updates of materials package for NCSG.
28	5/13/2020	Kim, Ye Darm	1.1	Process revisions analysis re: YEE v. Actual 2019 results.
28	5/13/2020	Kim, Ye Darm	0.9	Prepare slide re: YEE v. 2019 Actual results analysis.
28	5/13/2020	Kurtz, Emma	0.8	Prepare revisions to outstanding IAC diligence requests tracker and accompanying slides.
28	5/13/2020	Kurtz, Emma	1.4	Prepare outstanding diligence requests for IAC 2020 business plan review to share with Counsel.
28	5/13/2020	Kurtz, Emma	0.3	Prepare list of parties in due diligence process in preparation for meeting with NCSG.
28	5/13/2020	Kurtz, Emma	0.8	Continue to prepare slides on variances between revised and original IAC budget for Counsel.
28	5/13/2020	Kurtz, Emma	0.6	Prepare revisions to analysis of variance re: revised and original IAC budgets.
28	5/13/2020	Kurtz, Emma	0.6	Prepare slides on variance between revised IAC budget and original IAC budget for Counsel.
28	5/13/2020	Bromberg, Brian	2.6	Review analysis re: IAC business plan variance.
28	5/13/2020	Bromberg, Brian	1.8	Review latest IAC diligence tracker for outstanding items.
28	5/13/2020	Bromberg, Brian	3.2	Review 2019 and future variance of new IAC business plan.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD MAY 1, 2020 TO MAY 31, 2020

Task Category	Date	Professional	Hours	Activity
28	5/14/2020	Diaz, Matthew	0.9	Review report to the committee re: diligence of the IACs.
28	5/14/2020	Kurtz, Emma	0.9	Update IAC business plan review outstanding diligence requests tracker and accompanying slides for Counsel.
28	5/14/2020	Bromberg, Brian	1.7	Review updated IAC diligence tracker for outstanding diligence items.
28	5/14/2020	Bromberg, Brian	0.8	Finalize list of IAC diligence parties.
28	5/14/2020	Bromberg, Brian	1.5	Review updated IAC business plan projections.
28	5/15/2020	Kim, Ye Darm	0.6	Prepare materials for sharing with the NCSG.
28	5/15/2020	Bromberg, Brian	0.4	Participate in call with Counsel to discuss IAC diligence response.
28	5/15/2020	Bromberg, Brian	1.3	Review and finalize IAC diligence tracker.
28	5/15/2020	Bromberg, Brian	1.1	Participate in call with NCSG re: diligence.
28	5/15/2020	Bromberg, Brian	0.7	Participate in internal discussion re: NCSG call.
28	5/15/2020	Bromberg, Brian	1.4	Prepare for call with NCSG re: diligence.
28	5/15/2020	Bromberg, Brian	0.9	Discuss NCSG call and documents with AHC advisors.
28	5/15/2020	Bromberg, Brian	1.6	Revise IAC business plan diligence update slides.
28	5/15/2020	Bromberg, Brian	1.0	Participate in discussion re: document sharing protocol.
28	5/18/2020	Diaz, Matthew	0.8	Perform detailed review of updated IAC diligence question list.
28	5/18/2020	Kurtz, Emma	0.7	Prepare analysis of revised IAC business plan and compile the relevant documents.
28	5/18/2020	Bromberg, Brian	2.2	Revise IAC diligence tracker for items received.
28	5/18/2020	Bromberg, Brian	1.3	Review latest IAC financial projections.
28	5/19/2020	Diaz, Matthew	2.3	Review and provide comments on the updated business plan diligence presentation.
28	5/19/2020	Kim, Ye Darm	0.5	Participate in internal meeting re: variances of IAC plans.
28	5/19/2020	Kurtz, Emma	1.4	Prepare revisions to IAC diligence process update presentation.
28	5/19/2020	Kurtz, Emma	1.3	Prepare EBITDA bridge analysis between the revised IAC business plan and the November plan.
28	5/19/2020	Kurtz, Emma	0.5	Discuss IAC diligence process and next steps.
28	5/19/2020	Kurtz, Emma	0.3	Prepare additional revisions to IAC diligence process update presentation per internal comments.
28	5/19/2020	Bromberg, Brian	1.6	Participate in internal discussion re: IAC presentation.
28	5/19/2020	Bromberg, Brian	1.3	Review latest IAC diligence presentation draft.
28	5/19/2020	Bromberg, Brian	1.7	Continue review of latest IAC diligence presentation draft.
28	5/19/2020	Bromberg, Brian	2.3	Finalize draft of IAC presentation to send to AHC advisors.
28	5/20/2020	Diaz, Matthew	0.7	Participate in call with Alix to discuss the open IAC items and related next steps.
28	5/20/2020	Kim, Ye Darm	0.4	Participate in internal call re: IAC diligence workplan.
28	5/20/2020	Bromberg, Brian	1.0	Review updated IAC diligence request list.
28	5/20/2020	Bromberg, Brian	1.8	Review latest IAC business plan projection support file.
28	5/20/2020	Bromberg, Brian	0.9	Finalize and send IAC diligence list to Company advisors.
28	5/20/2020	Bromberg, Brian	0.5	Participate in discussion re: IAC diligence with Debtor advisors.
28	5/20/2020	Bromberg, Brian	1.6	Coordinate with HL on preparing summary of valuation information and considerations.
28	5/22/2020	Diaz, Matthew	0.7	Perform review of the updated IAC diligence presentation.
28	5/22/2020	Kurtz, Emma	0.4	Prepare document approval request list re: IAC diligence process update presentation to send to Counsel.
28	5/22/2020	Bromberg, Brian	0.9	Review list of documents relied upon for prior IAC report.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD MAY 1, 2020 TO MAY 31, 2020

Task Category	Date	Professional	Hours	Activity
28	5/22/2020	Bromberg, Brian	0.8	Continue to process revisions to IAC business plan diligence presentation.
28	5/22/2020	Bromberg, Brian	0.7	Review list of documents relied upon for draft IAC report.
28	5/22/2020	Bromberg, Brian	0.7	Review new IAC diligence response files for business plan support.
28	5/22/2020	Bromberg, Brian	1.5	Continue review of IAC business plan diligence presentation.
28	5/26/2020	Diaz, Matthew	1.7	Perform review of the updated IAC business plan due diligence presentation.
28	5/26/2020	Kurtz, Emma	1.9	Analyze 2020-2024 price/volume information received from the Company to compare to revised budget.
28	5/26/2020	Bromberg, Brian	0.9	Continue review of newly provided price volume files supporting the IAC business plan.
28	5/26/2020	Bromberg, Brian	2.3	Review newly provided price volume files supporting the IAC business plan.
28	5/27/2020	Diaz, Matthew	0.7	Review Huron's responses to IAC open diligence item questions.
28	5/27/2020	Diaz, Matthew	0.6	Participate in call with Counsel re: open IAC due diligence.
28	5/27/2020	Kurtz, Emma	0.6	Prepare revisions to list of IACs and Sackler persons, trusts, and entities, per internal comments.
28	5/27/2020	Kurtz, Emma	2.7	Prepare comprehensive list of IACs and covered Sackler persons, trusts, and entities re: analysis of cash transfers.
28	5/27/2020	Kurtz, Emma	0.7	Discuss outstanding diligence process items and identify next steps of business plan review.
28	5/27/2020	Bromberg, Brian	0.9	Review document relied upon list for IAC presentation.
28	5/27/2020	Bromberg, Brian	0.8	Discuss IAC diligence with team and counsel re: next steps.
28	5/27/2020	Bromberg, Brian	0.3	Discuss IAC business plan diligence workplan with team.
28	5/27/2020	Bromberg, Brian	1.0	Prepare for call with team re: IAC business plan diligence workplan.
28	5/29/2020	Diaz, Matthew	1.6	Review analysis re: IAC country level due diligence information.
28	5/29/2020	Bromberg, Brian	1.8	Review latest draft of IAC business plan presentation and provide comments.
28 Total			123.6	
Grand Total			398.2	

EXHIBIT D

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

SUMMARY OF EXPENSES

FOR THE PERIOD MAY 1, 2020 TO MAY 31, 2020

Expense Type	Amount
Other	\$ 4,325.26
Grand Total	\$ 4,325.26

EXHIBIT E
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
EXPENSE DETAIL
FOR THE PERIOD MAY 1, 2020 TO MAY 31, 2020

Date	Professional	Expense Type	Expense Detail	Amount
4/30/2020	Butterfield, Linda	Other	Access to Lexis Nexis for research regarding the HRT motion.	\$ 29.70
4/30/2020	Harsha, Adam	Other	Access to Lexis Nexis for research regarding the HRT motion.	10.05
5/1/2020	Butterfield, Linda	Other	Access to TransUnion for research regarding the HRT motion.	29.60
5/1/2020	Harsha, Adam	Other	Access to Thomson Reuters for research regarding the HRT motion.	3,004.17
5/1/2020	Harsha, Adam	Other	Access to TransUnion for research regarding the HRT motion.	32.20
5/1/2020	Causton, Daniel	Other	Access to Factiva for research regarding the HRT motion.	1,013.44
5/7/2020	Butterfield, Linda	Other	Invoice for Allegheny Country court searches for research regarding the HRT motion.	140.00
5/31/2020	Causton, Daniel	Other	Access to Lexis Nexis for research regarding the HRT motion.	66.10
Other Total				\$ 4,325.26
Grand Total				\$ 4,325.26